Eduardo Tormo

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Topics

Cancer Stem Cells

Chronic Lymphocytic Leukemia

Top Venues

International journal of molecular sciences

Cell death discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer. Cell death discovery 10 (1) (2024)
Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer. Cell death discovery 10 (1) (2024)
Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer. Cell death discovery 10 (1) (2024)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Ballester, Begoña Pineda, Patricia Rodrigues, Eduardo Tormo, María José Terol, Pilar Eroles
Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia. Genes 11 (6) (2020)
Sara S Oltra, Juan Miguel Cejalvo, Eduardo Tormo, Marta Albanell, Ana Ferrer, Marta Nacher, Begoña Bermejo, Cristina Hernando, Isabel Chirivella, Elisa Alonso, Octavio Burgués, Maria Peña-Chilet, Pilar Eroles, Ana Lluch, Gloria Ribas, María Teresa Martinez
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women. Cancers 12 (2) (2020)